by Keyword: Natural-killer-cells
Hinnekens, C, Harizaj, A, Berdecka, D, Aernout, I, Shariati, M, Peeters, S, Lion, E, De Smedt, SC, Vandekerckhove, B, Braeckmans, K, Fraire, JC, (2024). Photoporation of NK-92MI cells with biodegradable polydopamine nanosensitizers as a promising strategy for the generation of engineered NK cell therapies Applied Materials Today 40, 102402
Chimeric antigen receptor (CAR)-T cells have made significant advancements in the field of adoptive immune cell therapies and the treatment of hematological malignancies. However, there are several drawbacks associated with the production and administration of these therapies. As a result, there has been interest in using natural killer (NK) cells to develop allogeneic CAR-NK cell therapies instead. While viral transduction is powerful for engineering T cells, NK cells have shown limited efficacy and high toxicity with this method. Therefore, efforts are being made to optimize non-viral transfection technologies for engineering NK cells. One such emerging technology is photoporation, which has demonstrated high efficiency and versatility for transfecting different immune cells. In this study, we evaluated the potential of nanoparticle-sensitized photoporation for genetic engineering of NK cells. Our findings show that both FD500 and eGFP mRNA can be successfully delivered into NK-92MI cells with high efficiency and low toxicity. When compared to state-of-the-art electroporation, photoporation proved to be more efficient, gentle, and capable of preserving the phenotype of NK-92MI cells. Overall, our work highlights the promising prospects of photoporation for NK cell engineering.
JTD Keywords: Cancer immunotherapie, Car, Cell engineering, Deliver, Messenger-rna, Nanoparticles, Natural killer cells, Natural-killer-cells, Photoporation, Polydopamine nanoparticles, T-cells
Hinnekens, C, De Smedt, SC, Fraire, JC, Braeckmans, K, (2023). Non-viral engineering of NK cells Biotechnology Advances 68, 108212
The last decade has witnessed great progress in the field of adoptive cell therapies, with the authorization of Kymriah (tisagenlecleucel) in 2017 by the Food and Drug Administration (FDA) as a crucial stepstone. Since then, five more CAR-T therapies have been approved for the treatment of hematological malignancies. While this is a great step forward to treating several types of blood cancers, CAR-T cell therapies are still associated with severe side-effects such as Graft-versus-Host Disease (GvHD), cytokine release syndrome (CRS) and neurotoxicity. Because of this, there has been continued interest in Natural Killer cells which avoid these side-effects while offering the possibility to generate allogeneic cell therapies. Similar to T-cells, NK cells can be genetically modified to improve their therapeutic efficacy in a variety of ways. In contrast to T cells, viral transduction of NK cells remains inefficient and induces cytotoxic effects. Viral vectors also require a lengthy and expensive product development process and are accompanied by certain risks such as insertional mutagenesis. Therefore, non-viral transfection technologies are avidly being developed aimed at addressing these shortcomings of viral vectors. In this review we will present an overview of the potential of NK cells in cancer immunotherapies and the non-viral transfection technologies that have been explored to engineer them.Copyright © 2023 Elsevier Inc. All rights reserved.
JTD Keywords: adoptive cell therapy, cancer immunotherapy, immunotherapy, messenger-rna delivery, nanoparticle, nk cells, non -viral engineering, sonoporation, t-cell, transfection, ultrasound, Adoptive cell therapy, Cancer immunotherapy, Cell engineering, Natural-killer-cells, Nk cells, Non-viral engineering